Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas

Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas

Chimeric antigen receptor (CAR)-T cells targeting CD30 have demonstrated high response rates with durable remissions observed in a subset of patients with relapsed/refractory CD30+ hematologic malignancies, particularly classical Hodgkin lymphoma. This therapy has low rates of toxicity including cyt...

Full description

Bibliographic Details
Main Authors: Barbara Savoldo, Gianpietro Dotti, Allison M Deal, Jonathan S Serody, Christopher Dittus, Nicholas P Tschernia, Hillary Heiling, Catherine Cheng, Caroline Babinec, Megan Gonzalez, J Kaitlin Morrison, Anne W Beaven, William A Wood, Natalie S Grover
Format: Article
Language:English
Published: BMJ Publishing Group 2023-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/8/e006959.full

Internet

https://jitc.bmj.com/content/11/8/e006959.full

Similar Items